Integrated Investment Consultants’s Ionis Pharmaceuticals IONS Stock Holding History

Integrated Investment Consultants’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-317	Closed	-$14K	–	435
2018 Q1	$14K	Buy	+317	New	+$16.1K	0.01%	586
2017 Q3	$16K	Sell	317 -105	-25%	-$5.5K	0.01%	488
2017 Q2	$21K	Hold	422	–	–	0.01%	461
2017 Q1	$17K	Hold	422	–	–	0.01%	473
2016 Q4	$20K	Buy	422 +195	+86%	+$7.72K	0.01%	457
2016 Q3	$7K	Hold	227	–	–	﹤0.01%	532
2016 Q2	$5K	Hold	227	–	–	﹤0.01%	560
2016 Q1	$9K	Buy	+227	New	+$9.22K	0.01%	511

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Integrated Investment Consultants's IONS Position: Q2 2018 in Review

Integrated Investment Consultants sold out of Ionis Pharmaceuticals (IONS) in Q2 2018, closing a stake of 317 shares — an estimated $14K sold.

Integrated Investment Consultants first reported a position in IONS in Q1 2016 and held it in 8 quarters. The position peaked at $21K in Q2 2017. 307 funds tracked by Wall St. Rank hold IONS as of Q2 2018.

Integrated Investment Consultants reported no remaining Ionis Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Integrated Investment Consultants sold 317 Ionis Pharmaceuticals shares in Q2 2018, an estimated $14K.
Integrated Investment Consultants first reported a position in Ionis Pharmaceuticals in Q1 2016 and held it in 8 quarters.
Integrated Investment Consultants's Ionis Pharmaceuticals position peaked at $21K in Q2 2017.
307 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2018.

Based on Integrated Investment Consultants's 13F filing for Q2 2018, filed 1 Aug 2018.